KPIs & Operating Metrics(New)

Balance Sheet

Accounts Payables Accumulated Expenses Assets Capital Leases Cash & Current Investments Cash & Equivalents Common Equity Convertible Debt Current Assets Current Deferred Revenue Current Deferred Tax Assets Current Deferred Tax Assets Current Leases Finished Goods Goodwill Goodwill & Intangibles Intangibles Inventory Liabilities and Shareholders Equity Long-Term Deferred Tax Non-Current Assets Non-Current Debt Non-Current Deferred Tax Liability Non-Current Deferred Tax Liability Non-Current Deffered Revenue Operating Leases Other Accumulated Expenses Other Non-Current Assets Other Non-Current Liabilities Payables Preferred Shares Prepaid Assets Property, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw Materials Receivables Receivables - Net Receivables - Other Retained Earnings Shareholder's Equity Shares Outstanding Short term Debt Short-term Investments Total Current Liabilities Total Debt Total Liabilities Total Non-Current Liabilities Treasury Shares Treasury Shares Work In Process

Cash Flow Statement

Daily Values

Growth Metrics

Others

ClearPoint Neuro (CLPT) Notes Payables (2017 - 2024)

ClearPoint Neuro's Notes Payables history spans 8 years, with the latest figure at $10.0 million for Q2 2024.

On a quarterly basis, Notes Payables changed N/A to $10.0 million in Q2 2024 year-over-year; TTM through Jun 2024 was $10.0 million, a N/A change, with the full-year FY2017 number at $1.9 million, changed N/A from a year prior.
Notes Payables hit $10.0 million in Q2 2024 for ClearPoint Neuro, roughly flat from $10.0 million in the prior quarter.
Over the last five years, Notes Payables for CLPT hit a ceiling of $10.0 million in Q2 2024 and a floor of $10.0 million in Q1 2024.